CA2540843A1 - Derives de carboxamide de phenyle et de sulfonamide utilisables comme 11-beta-hydroxysteroide deshydrogenase - Google Patents
Derives de carboxamide de phenyle et de sulfonamide utilisables comme 11-beta-hydroxysteroide deshydrogenase Download PDFInfo
- Publication number
- CA2540843A1 CA2540843A1 CA002540843A CA2540843A CA2540843A1 CA 2540843 A1 CA2540843 A1 CA 2540843A1 CA 002540843 A CA002540843 A CA 002540843A CA 2540843 A CA2540843 A CA 2540843A CA 2540843 A1 CA2540843 A1 CA 2540843A1
- Authority
- CA
- Canada
- Prior art keywords
- arh
- compound according
- mmol
- nmr
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title description 9
- 229940124530 sulfonamide Drugs 0.000 title description 5
- 150000003456 sulfonamides Chemical class 0.000 title description 4
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 title 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 201
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 42
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 41
- 125000003118 aryl group Chemical group 0.000 claims abstract description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 18
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 17
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 17
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims description 133
- 239000000203 mixture Substances 0.000 claims description 129
- 238000000034 method Methods 0.000 claims description 86
- 238000003556 assay Methods 0.000 claims description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 26
- 150000001412 amines Chemical class 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 230000002401 inhibitory effect Effects 0.000 claims description 18
- 150000001408 amides Chemical class 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 125000002837 carbocyclic group Chemical group 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 6
- 208000005838 apparent mineralocorticoid excess syndrome Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 6
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 125000005429 oxyalkyl group Chemical group 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 230000002411 adverse Effects 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 208000009888 Adrenocortical Adenoma Diseases 0.000 claims description 3
- 201000000736 Amenorrhea Diseases 0.000 claims description 3
- 206010001928 Amenorrhoea Diseases 0.000 claims description 3
- 208000020084 Bone disease Diseases 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000014311 Cushing syndrome Diseases 0.000 claims description 3
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 3
- 206010070531 Foetal growth restriction Diseases 0.000 claims description 3
- 206010020112 Hirsutism Diseases 0.000 claims description 3
- 206010035104 Pituitary tumour Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 208000015234 adrenal cortex adenoma Diseases 0.000 claims description 3
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 3
- 201000003354 adrenal cortical adenoma Diseases 0.000 claims description 3
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 3
- 231100000540 amenorrhea Toxicity 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 208000030941 fetal growth restriction Diseases 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 208000024312 invasive carcinoma Diseases 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 22
- 239000003112 inhibitor Substances 0.000 abstract description 16
- 101710088194 Dehydrogenase Proteins 0.000 abstract description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 546
- 229910052739 hydrogen Inorganic materials 0.000 description 358
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 265
- 235000019439 ethyl acetate Nutrition 0.000 description 197
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 191
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 180
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 150
- 239000000243 solution Substances 0.000 description 146
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 130
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 125
- 239000007787 solid Substances 0.000 description 125
- 238000005481 NMR spectroscopy Methods 0.000 description 119
- 238000004128 high performance liquid chromatography Methods 0.000 description 111
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 108
- 238000004809 thin layer chromatography Methods 0.000 description 96
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 70
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 68
- 230000003228 microsomal effect Effects 0.000 description 64
- 230000015572 biosynthetic process Effects 0.000 description 61
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 61
- 238000003786 synthesis reaction Methods 0.000 description 60
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 59
- 238000006243 chemical reaction Methods 0.000 description 59
- 229960004544 cortisone Drugs 0.000 description 59
- 229960000890 hydrocortisone Drugs 0.000 description 59
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 56
- 239000012267 brine Substances 0.000 description 55
- 210000004027 cell Anatomy 0.000 description 55
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 55
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 54
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 54
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 54
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 54
- 238000003818 flash chromatography Methods 0.000 description 53
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 52
- 108090000623 proteins and genes Proteins 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 50
- 102000004190 Enzymes Human genes 0.000 description 47
- 108090000790 Enzymes Proteins 0.000 description 47
- 238000005160 1H NMR spectroscopy Methods 0.000 description 44
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 43
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 43
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 42
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 42
- 239000000843 powder Substances 0.000 description 42
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 40
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 40
- 230000002440 hepatic effect Effects 0.000 description 39
- 101150041968 CDC13 gene Proteins 0.000 description 38
- 239000000872 buffer Substances 0.000 description 38
- 101100451537 Caenorhabditis elegans hsd-1 gene Proteins 0.000 description 36
- 239000012074 organic phase Substances 0.000 description 36
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 35
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 34
- 230000005764 inhibitory process Effects 0.000 description 32
- 239000012043 crude product Substances 0.000 description 29
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 28
- 238000001952 enzyme assay Methods 0.000 description 28
- 229920006395 saturated elastomer Polymers 0.000 description 28
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 27
- 229960003720 enoxolone Drugs 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- 239000003862 glucocorticoid Substances 0.000 description 26
- 238000011534 incubation Methods 0.000 description 26
- 238000003127 radioimmunoassay Methods 0.000 description 26
- 239000012044 organic layer Substances 0.000 description 25
- 238000000746 purification Methods 0.000 description 25
- 239000000758 substrate Substances 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 210000001589 microsome Anatomy 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 230000001351 cycling effect Effects 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- -1 tent-butyl Chemical group 0.000 description 20
- 229940037128 systemic glucocorticoids Drugs 0.000 description 19
- 229930192474 thiophene Natural products 0.000 description 19
- 125000004122 cyclic group Chemical group 0.000 description 18
- 239000003480 eluent Substances 0.000 description 18
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 17
- 239000012131 assay buffer Substances 0.000 description 16
- ZSIYKAQPQRTBPF-UHFFFAOYSA-N 3-chloro-2-methylbenzenesulfonyl chloride Chemical compound CC1=C(Cl)C=CC=C1S(Cl)(=O)=O ZSIYKAQPQRTBPF-UHFFFAOYSA-N 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 238000007429 general method Methods 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 235000011152 sodium sulphate Nutrition 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 238000002425 crystallisation Methods 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 13
- 238000007792 addition Methods 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 229940088597 hormone Drugs 0.000 description 12
- 239000005556 hormone Substances 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 12
- 229920000053 polysorbate 80 Polymers 0.000 description 12
- XEKLXLHCNBKGDJ-UHFFFAOYSA-N 4-chloro-2-methyl-1,3-benzothiazol-5-amine Chemical compound NC1=CC=C2SC(C)=NC2=C1Cl XEKLXLHCNBKGDJ-UHFFFAOYSA-N 0.000 description 11
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 11
- 102100021316 Mineralocorticoid receptor Human genes 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000010828 elution Methods 0.000 description 11
- 125000001188 haloalkyl group Chemical group 0.000 description 11
- 238000003018 immunoassay Methods 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 150000003431 steroids Chemical class 0.000 description 11
- 125000002009 alkene group Chemical group 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- LEFGAGRZHLNPLS-UHFFFAOYSA-N 4-propylbenzenesulfonyl chloride Chemical compound CCCC1=CC=C(S(Cl)(=O)=O)C=C1 LEFGAGRZHLNPLS-UHFFFAOYSA-N 0.000 description 9
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 9
- 229960000530 carbenoxolone Drugs 0.000 description 9
- 210000000349 chromosome Anatomy 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 239000002395 mineralocorticoid Substances 0.000 description 9
- 239000012089 stop solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 8
- 230000006820 DNA synthesis Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- NZYPCJXREKMMCJ-UHFFFAOYSA-N 4-propylbenzoyl chloride Chemical compound CCCC1=CC=C(C(Cl)=O)C=C1 NZYPCJXREKMMCJ-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 102000018594 Tumour necrosis factor Human genes 0.000 description 7
- 108050007852 Tumour necrosis factor Proteins 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- RBKHNGHPZZZJCI-UHFFFAOYSA-N (4-aminophenyl)-phenylmethanone Chemical compound C1=CC(N)=CC=C1C(=O)C1=CC=CC=C1 RBKHNGHPZZZJCI-UHFFFAOYSA-N 0.000 description 6
- QVTQYSFCFOGITD-UHFFFAOYSA-N 2,5-dichlorobenzoic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1Cl QVTQYSFCFOGITD-UHFFFAOYSA-N 0.000 description 6
- HVLUYXIJZLDNIS-UHFFFAOYSA-N 2-thiophen-2-ylethanamine Chemical compound NCCC1=CC=CS1 HVLUYXIJZLDNIS-UHFFFAOYSA-N 0.000 description 6
- JPVUWCPKMYXOKW-UHFFFAOYSA-N 4-phenylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1=CC=CC=C1 JPVUWCPKMYXOKW-UHFFFAOYSA-N 0.000 description 6
- HODOSJNSRPXYBH-UHFFFAOYSA-N 5-amino-2,3-dihydroinden-1-one Chemical compound NC1=CC=C2C(=O)CCC2=C1 HODOSJNSRPXYBH-UHFFFAOYSA-N 0.000 description 6
- BEVVUJBVEXJGKM-UHFFFAOYSA-N 6-amino-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(N)=CC=C21 BEVVUJBVEXJGKM-UHFFFAOYSA-N 0.000 description 6
- 108091060290 Chromatid Proteins 0.000 description 6
- 210000004718 centriole Anatomy 0.000 description 6
- 210000004756 chromatid Anatomy 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000016507 interphase Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- GPRYKVSEZCQIHD-UHFFFAOYSA-N 1-(4-aminophenyl)ethanone Chemical compound CC(=O)C1=CC=C(N)C=C1 GPRYKVSEZCQIHD-UHFFFAOYSA-N 0.000 description 5
- BXCOSWRSIISQSL-UHFFFAOYSA-N 2,5-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(Cl)C(S(Cl)(=O)=O)=C1 BXCOSWRSIISQSL-UHFFFAOYSA-N 0.000 description 5
- GGHLXLVPNZMBQR-UHFFFAOYSA-N 3,5-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC(Cl)=CC(Cl)=C1 GGHLXLVPNZMBQR-UHFFFAOYSA-N 0.000 description 5
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 150000001263 acyl chlorides Chemical class 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 239000003610 charcoal Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000004110 gluconeogenesis Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000011278 mitosis Effects 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- KSYPAYCLSJHBKA-UHFFFAOYSA-N 1,2-benzoxazol-5-amine Chemical compound NC1=CC=C2ON=CC2=C1 KSYPAYCLSJHBKA-UHFFFAOYSA-N 0.000 description 4
- QBZGAULXCVZXFL-UHFFFAOYSA-N 2,3-dimethylquinoxalin-6-amine Chemical compound C1=C(N)C=C2N=C(C)C(C)=NC2=C1 QBZGAULXCVZXFL-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- YKFVEQQFGNMNCH-UHFFFAOYSA-N 2-methylquinoxalin-6-amine Chemical compound C1=C(N)C=CC2=NC(C)=CN=C21 YKFVEQQFGNMNCH-UHFFFAOYSA-N 0.000 description 4
- WDDYNCREWBOZLG-UHFFFAOYSA-N 3-methyl-1,2-benzoxazol-5-amine Chemical compound C1=C(N)C=C2C(C)=NOC2=C1 WDDYNCREWBOZLG-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 4
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 229960002478 aldosterone Drugs 0.000 description 4
- 230000001837 anti-cortisol effect Effects 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 230000021953 cytokinesis Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- BPODRHUUQPTSHB-UHFFFAOYSA-N n-(4-chloro-2-methyl-1,3-benzothiazol-5-yl)-4-phenylbenzamide Chemical compound C=1C=C2SC(C)=NC2=C(Cl)C=1NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 BPODRHUUQPTSHB-UHFFFAOYSA-N 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- MSGRFBKVMUKEGZ-UHFFFAOYSA-N quinoxalin-6-amine Chemical compound N1=CC=NC2=CC(N)=CC=C21 MSGRFBKVMUKEGZ-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- ZUPYTANKWDPRDP-UHFFFAOYSA-N 1-benzothiophen-5-amine Chemical compound NC1=CC=C2SC=CC2=C1 ZUPYTANKWDPRDP-UHFFFAOYSA-N 0.000 description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 3
- BPWUIVGFGOGGHR-UHFFFAOYSA-N 2-methyl-1-benzofuran-5-amine Chemical compound NC1=CC=C2OC(C)=CC2=C1 BPWUIVGFGOGGHR-UHFFFAOYSA-N 0.000 description 3
- TYJFYUVDUUACKX-UHFFFAOYSA-N 2-methylquinolin-6-amine Chemical compound C1=C(N)C=CC2=NC(C)=CC=C21 TYJFYUVDUUACKX-UHFFFAOYSA-N 0.000 description 3
- IRUXPIPZLCHAKN-UHFFFAOYSA-N 3-methyl-1-benzofuran-5-amine Chemical compound C1=C(N)C=C2C(C)=COC2=C1 IRUXPIPZLCHAKN-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 241000473945 Theria <moth genus> Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008512 biological response Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000004190 glucose uptake Effects 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- OLLMSIUDBMURHQ-UHFFFAOYSA-N methyl 5-amino-1-benzofuran-2-carboxylate Chemical compound NC1=CC=C2OC(C(=O)OC)=CC2=C1 OLLMSIUDBMURHQ-UHFFFAOYSA-N 0.000 description 3
- SIMBULBEQVHFPK-UHFFFAOYSA-N methyl 5-amino-1-benzothiophene-2-carboxylate Chemical compound NC1=CC=C2SC(C(=O)OC)=CC2=C1 SIMBULBEQVHFPK-UHFFFAOYSA-N 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- QNCYJBXITNKHKI-UHFFFAOYSA-N n-acetyl-n-(5-amino-1,2-benzothiazol-3-yl)acetamide Chemical compound C1=C(N)C=C2C(N(C(C)=O)C(=O)C)=NSC2=C1 QNCYJBXITNKHKI-UHFFFAOYSA-N 0.000 description 3
- 230000006764 neuronal dysfunction Effects 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- XFGPXURFKAUHQR-UHFFFAOYSA-N quinazolin-6-amine Chemical compound N1=CN=CC2=CC(N)=CC=C21 XFGPXURFKAUHQR-UHFFFAOYSA-N 0.000 description 3
- RJSRSRITMWVIQT-UHFFFAOYSA-N quinolin-6-amine Chemical compound N1=CC=CC2=CC(N)=CC=C21 RJSRSRITMWVIQT-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- DULNUPMHDGXSMH-UHFFFAOYSA-N 2,5-dichloro-n-(4-chloro-2-methyl-1,3-benzothiazol-5-yl)benzamide Chemical compound C=1C=C2SC(C)=NC2=C(Cl)C=1NC(=O)C1=CC(Cl)=CC=C1Cl DULNUPMHDGXSMH-UHFFFAOYSA-N 0.000 description 2
- LACSJSVKZSNSMJ-UHFFFAOYSA-N 2,5-dichloro-n-(5-oxo-7,8-dihydro-6h-naphthalen-2-yl)benzamide Chemical compound ClC1=CC=C(Cl)C(C(=O)NC=2C=C3CCCC(=O)C3=CC=2)=C1 LACSJSVKZSNSMJ-UHFFFAOYSA-N 0.000 description 2
- CZWQHNDESNJXGS-UHFFFAOYSA-N 2-methyl-6-nitroquinoxaline Chemical compound C1=C([N+]([O-])=O)C=CC2=NC(C)=CN=C21 CZWQHNDESNJXGS-UHFFFAOYSA-N 0.000 description 2
- VODQTYKGHKTBAF-UHFFFAOYSA-N 3,5-dichloro-n-(4-chloro-2-methyl-1,3-benzothiazol-5-yl)benzamide Chemical compound C=1C=C2SC(C)=NC2=C(Cl)C=1NC(=O)C1=CC(Cl)=CC(Cl)=C1 VODQTYKGHKTBAF-UHFFFAOYSA-N 0.000 description 2
- JNYBJMIAQFMYRO-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)sulfanylmethyl]thiophene Chemical compound ClC1=CC=C(Cl)C(SCC2=CSC=C2)=C1 JNYBJMIAQFMYRO-UHFFFAOYSA-N 0.000 description 2
- UADQGJRNKGBTMC-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)sulfonylmethyl]thiophene Chemical compound ClC1=CC=C(Cl)C(S(=O)(=O)CC2=CSC=C2)=C1 UADQGJRNKGBTMC-UHFFFAOYSA-N 0.000 description 2
- JNHSAFLZAPLSBT-UHFFFAOYSA-N 3-methoxy-n-(5-oxo-7,8-dihydro-6h-naphthalen-2-yl)benzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C3CCCC(=O)C3=CC=2)=C1 JNHSAFLZAPLSBT-UHFFFAOYSA-N 0.000 description 2
- OQGHIIIOEJLEDE-UHFFFAOYSA-N 3-methyl-1-benzothiophen-5-amine Chemical compound C1=C(N)C=C2C(C)=CSC2=C1 OQGHIIIOEJLEDE-UHFFFAOYSA-N 0.000 description 2
- SXLMAPJOAHBIJZ-UHFFFAOYSA-N 3-methyl-5-nitro-1-benzofuran Chemical compound C1=C([N+]([O-])=O)C=C2C(C)=COC2=C1 SXLMAPJOAHBIJZ-UHFFFAOYSA-N 0.000 description 2
- ZHFCNWVBMJIBPC-UHFFFAOYSA-N 3-methyl-5-nitro-1-benzothiophene Chemical compound C1=C([N+]([O-])=O)C=C2C(C)=CSC2=C1 ZHFCNWVBMJIBPC-UHFFFAOYSA-N 0.000 description 2
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 2
- NLFVITKESIOKCO-UHFFFAOYSA-N 4-amino-3-chloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=C(Cl)C(N)=CC=2)=N1 NLFVITKESIOKCO-UHFFFAOYSA-N 0.000 description 2
- NLESYSQTERIDQP-UHFFFAOYSA-N 4-amino-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound NC1=CC=C(S(=O)(=O)NCCO)C=C1 NLESYSQTERIDQP-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- APUJHWISPUJTRV-UHFFFAOYSA-N 4-methoxy-n-(5-oxo-7,8-dihydro-6h-naphthalen-2-yl)benzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=C(C(=O)CCC2)C2=C1 APUJHWISPUJTRV-UHFFFAOYSA-N 0.000 description 2
- NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 2
- UJFLVFKOALOCTO-UHFFFAOYSA-N 5-[(2,5-dichlorophenyl)sulfanylmethyl]-2-methyl-1,3-benzothiazole Chemical compound C=1C=C2SC(C)=NC2=CC=1CSC1=CC(Cl)=CC=C1Cl UJFLVFKOALOCTO-UHFFFAOYSA-N 0.000 description 2
- FKPXGNGUVSHWQQ-UHFFFAOYSA-N 5-methyl-1,2-oxazol-3-amine Chemical compound CC1=CC(N)=NO1 FKPXGNGUVSHWQQ-UHFFFAOYSA-N 0.000 description 2
- YLKFDRWBZAALPN-UHFFFAOYSA-N 6-nitroquinoxaline Chemical compound N1=CC=NC2=CC([N+](=O)[O-])=CC=C21 YLKFDRWBZAALPN-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 2
- GXPIUNZCALHVBA-UHFFFAOYSA-N N-acetylsulfamethoxazole Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NC1=NOC(C)=C1 GXPIUNZCALHVBA-UHFFFAOYSA-N 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 description 2
- 108010048287 Short Chain Dehydrogenase-Reductases Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 102000014034 Transcortin Human genes 0.000 description 2
- 108010011095 Transcortin Proteins 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BJVWOACJHDOISP-UHFFFAOYSA-N benzamide;1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1.NC(=O)C1=CC=CC=C1 BJVWOACJHDOISP-UHFFFAOYSA-N 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000002230 centromere Anatomy 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 108091008361 cortisol binding proteins Proteins 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- OSVZEJHBIFIMJF-UHFFFAOYSA-N methyl 5-nitro-1-benzothiophene-2-carboxylate Chemical compound [O-][N+](=O)C1=CC=C2SC(C(=O)OC)=CC2=C1 OSVZEJHBIFIMJF-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- WUPSRWUAZFUIPM-UHFFFAOYSA-N n-(1-oxo-2,3-dihydroinden-5-yl)-4-phenylbenzamide Chemical compound C=1C=C2C(=O)CCC2=CC=1NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 WUPSRWUAZFUIPM-UHFFFAOYSA-N 0.000 description 2
- XDJXZRJFCOWJRJ-UHFFFAOYSA-N n-(2-methyl-1,3-benzothiazol-5-yl)-4-propylbenzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)NC1=CC=C(SC(C)=N2)C2=C1 XDJXZRJFCOWJRJ-UHFFFAOYSA-N 0.000 description 2
- NAWKIVRBELKSAA-UHFFFAOYSA-N n-(4-acetylphenyl)-2,5-dichlorobenzamide Chemical compound C1=CC(C(=O)C)=CC=C1NC(=O)C1=CC(Cl)=CC=C1Cl NAWKIVRBELKSAA-UHFFFAOYSA-N 0.000 description 2
- HDBXOZMOFZQANE-UHFFFAOYSA-N n-(4-acetylphenyl)-3,5-dichlorobenzamide Chemical compound C1=CC(C(=O)C)=CC=C1NC(=O)C1=CC(Cl)=CC(Cl)=C1 HDBXOZMOFZQANE-UHFFFAOYSA-N 0.000 description 2
- SDRGCWJMBSFUDK-UHFFFAOYSA-N n-(4-acetylphenyl)-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C(C)=O)=C1 SDRGCWJMBSFUDK-UHFFFAOYSA-N 0.000 description 2
- OZBJBHMULRQFKG-UHFFFAOYSA-N n-(4-acetylphenyl)-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=C(C(C)=O)C=C1 OZBJBHMULRQFKG-UHFFFAOYSA-N 0.000 description 2
- RTOMUFLVUUQGRB-UHFFFAOYSA-N n-(4-acetylphenyl)-4-phenylbenzamide Chemical compound C1=CC(C(=O)C)=CC=C1NC(=O)C1=CC=C(C=2C=CC=CC=2)C=C1 RTOMUFLVUUQGRB-UHFFFAOYSA-N 0.000 description 2
- CWKQFIAVAMVIKE-UHFFFAOYSA-N n-(4-acetylphenyl)-4-propylbenzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)NC1=CC=C(C(C)=O)C=C1 CWKQFIAVAMVIKE-UHFFFAOYSA-N 0.000 description 2
- HZRFAWIDVNNDMT-UHFFFAOYSA-N n-(4-benzoylphenyl)-2,5-dichlorobenzamide Chemical compound ClC1=CC=C(Cl)C(C(=O)NC=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)=C1 HZRFAWIDVNNDMT-UHFFFAOYSA-N 0.000 description 2
- WNBUKKJBRXMSFK-UHFFFAOYSA-N n-(4-chloro-2-methyl-1,3-benzothiazol-5-yl)-2-(2,4-dichlorophenyl)acetamide Chemical compound C=1C=C2SC(C)=NC2=C(Cl)C=1NC(=O)CC1=CC=C(Cl)C=C1Cl WNBUKKJBRXMSFK-UHFFFAOYSA-N 0.000 description 2
- LOKLBNHFOPCFDT-UHFFFAOYSA-N n-(4-chloro-2-methyl-1,3-benzothiazol-5-yl)-2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(=O)NC=2C(=C3N=C(C)SC3=CC=2)Cl)=C1 LOKLBNHFOPCFDT-UHFFFAOYSA-N 0.000 description 2
- OWRPFOKDMQINSP-UHFFFAOYSA-N n-(4-chloro-2-methyl-1,3-benzothiazol-5-yl)-2-(4-chlorophenyl)acetamide Chemical compound C=1C=C2SC(C)=NC2=C(Cl)C=1NC(=O)CC1=CC=C(Cl)C=C1 OWRPFOKDMQINSP-UHFFFAOYSA-N 0.000 description 2
- IIECGNXSEXOFFE-UHFFFAOYSA-N n-(4-chloro-2-methyl-1,3-benzothiazol-5-yl)-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(SC(C)=N2)C2=C1Cl IIECGNXSEXOFFE-UHFFFAOYSA-N 0.000 description 2
- HZCQMFYMTDTHIX-UHFFFAOYSA-N n-(4-chloro-2-methyl-1,3-benzothiazol-5-yl)-4-propylbenzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)NC1=CC=C(SC(C)=N2)C2=C1Cl HZCQMFYMTDTHIX-UHFFFAOYSA-N 0.000 description 2
- RTBAIZLGIADEDB-UHFFFAOYSA-N n-(5-oxo-7,8-dihydro-6h-naphthalen-2-yl)-4-phenylbenzamide Chemical compound C=1C=C2C(=O)CCCC2=CC=1NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 RTBAIZLGIADEDB-UHFFFAOYSA-N 0.000 description 2
- UIYBZFJLZXBNRB-UHFFFAOYSA-N n-(5-oxo-7,8-dihydro-6h-naphthalen-2-yl)-4-propylbenzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)NC1=CC=C(C(=O)CCC2)C2=C1 UIYBZFJLZXBNRB-UHFFFAOYSA-N 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 201000005737 orchitis Diseases 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 229950009829 prasterone sulfate Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- DIJBBUIOWGGQOP-QGVNFLHTSA-N pregnenolone sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 DIJBBUIOWGGQOP-QGVNFLHTSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000031877 prophase Effects 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000026313 regulation of carbohydrate metabolic process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 229940043267 rhodamine b Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000016853 telophase Effects 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical class C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- XDRSTGHGOVMLRX-UHFFFAOYSA-N 2,3-dimethyl-6-nitroquinoxaline Chemical compound C1=C([N+]([O-])=O)C=C2N=C(C)C(C)=NC2=C1 XDRSTGHGOVMLRX-UHFFFAOYSA-N 0.000 description 1
- BCGINTHUBBPLLL-UHFFFAOYSA-N 2,4-dichloro-n-(1,2-dimethylbenzimidazol-5-yl)-n-methylbenzamide Chemical compound C=1C=C2N(C)C(C)=NC2=CC=1N(C)C(=O)C1=CC=C(Cl)C=C1Cl BCGINTHUBBPLLL-UHFFFAOYSA-N 0.000 description 1
- ZSVHZYQOZREVLA-UHFFFAOYSA-N 2,4-dichloro-n-(1,2-dimethylbenzimidazol-5-yl)benzamide Chemical compound C=1C=C2N(C)C(C)=NC2=CC=1NC(=O)C1=CC=C(Cl)C=C1Cl ZSVHZYQOZREVLA-UHFFFAOYSA-N 0.000 description 1
- ZQGYGCSQIASWQF-UHFFFAOYSA-N 2,5-dichloro-n,n-bis(thiophen-3-ylmethyl)benzenesulfonamide Chemical compound ClC1=CC=C(Cl)C(S(=O)(=O)N(CC2=CSC=C2)CC2=CSC=C2)=C1 ZQGYGCSQIASWQF-UHFFFAOYSA-N 0.000 description 1
- UCMBKBHAPCNZNS-UHFFFAOYSA-N 2,5-dichloro-n-(1-oxo-2,3-dihydroinden-5-yl)benzamide Chemical compound ClC1=CC=C(Cl)C(C(=O)NC=2C=C3CCC(=O)C3=CC=2)=C1 UCMBKBHAPCNZNS-UHFFFAOYSA-N 0.000 description 1
- XQXICBSFFDJHPG-UHFFFAOYSA-N 2,5-dichloro-n-(2-thiophen-2-ylethyl)benzamide Chemical compound ClC1=CC=C(Cl)C(C(=O)NCCC=2SC=CC=2)=C1 XQXICBSFFDJHPG-UHFFFAOYSA-N 0.000 description 1
- VEESUFUBMRYTAG-UHFFFAOYSA-N 2,5-dichloro-n-(2-thiophen-2-ylethyl)benzenesulfonamide Chemical compound ClC1=CC=C(Cl)C(S(=O)(=O)NCCC=2SC=CC=2)=C1 VEESUFUBMRYTAG-UHFFFAOYSA-N 0.000 description 1
- ZVEBDUNJTFURGF-UHFFFAOYSA-N 2,5-dichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC=C(Cl)C=2)Cl)=N1 ZVEBDUNJTFURGF-UHFFFAOYSA-N 0.000 description 1
- SKRYHFIGELLUQX-UHFFFAOYSA-N 2,5-dichloro-n-(thiophen-2-ylmethyl)benzenesulfonamide Chemical compound ClC1=CC=C(Cl)C(S(=O)(=O)NCC=2SC=CC=2)=C1 SKRYHFIGELLUQX-UHFFFAOYSA-N 0.000 description 1
- RNYNOPURJVLOQQ-UHFFFAOYSA-N 2,5-dichloro-n-(thiophen-3-ylmethyl)benzenesulfonamide Chemical compound ClC1=CC=C(Cl)C(S(=O)(=O)NCC2=CSC=C2)=C1 RNYNOPURJVLOQQ-UHFFFAOYSA-N 0.000 description 1
- QIULLHZMZMGGFH-UHFFFAOYSA-N 2,5-dichlorobenzenethiol Chemical compound SC1=CC(Cl)=CC=C1Cl QIULLHZMZMGGFH-UHFFFAOYSA-N 0.000 description 1
- GXMWLJKTGBZMBH-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C=C1Cl GXMWLJKTGBZMBH-UHFFFAOYSA-N 0.000 description 1
- UZUYKYNVSJTWEH-UHFFFAOYSA-N 2-(3-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=CC(CC(Cl)=O)=C1 UZUYKYNVSJTWEH-UHFFFAOYSA-N 0.000 description 1
- UMQUIRYNOVNYPA-UHFFFAOYSA-N 2-(4-chlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Cl)C=C1 UMQUIRYNOVNYPA-UHFFFAOYSA-N 0.000 description 1
- CXJOONIFSVSFAD-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=C(CC(Cl)=O)C=C1 CXJOONIFSVSFAD-UHFFFAOYSA-N 0.000 description 1
- VFVHWCKUHAEDMY-UHFFFAOYSA-N 2-chloro-5-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(Cl)C(C=O)=C1 VFVHWCKUHAEDMY-UHFFFAOYSA-N 0.000 description 1
- GPWQHYMVUZYWIK-UHFFFAOYSA-N 2-methyl-1,3-benzothiazol-5-amine Chemical compound NC1=CC=C2SC(C)=NC2=C1 GPWQHYMVUZYWIK-UHFFFAOYSA-N 0.000 description 1
- DTUGFHFJKMJXSO-UHFFFAOYSA-N 3,4-dimethoxybenzenesulfonic acid Chemical compound COC1=CC=C(S(O)(=O)=O)C=C1OC DTUGFHFJKMJXSO-UHFFFAOYSA-N 0.000 description 1
- WVUIBDIJPCRAGV-UHFFFAOYSA-N 3,5-dichloro-n-(2-methyl-1,3-benzothiazol-5-yl)benzamide Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)C1=CC(Cl)=CC(Cl)=C1 WVUIBDIJPCRAGV-UHFFFAOYSA-N 0.000 description 1
- YTNOEAOJDXEOAF-UHFFFAOYSA-N 3,5-dichloro-n-(2-thiophen-2-ylethyl)benzamide Chemical compound ClC1=CC(Cl)=CC(C(=O)NCCC=2SC=CC=2)=C1 YTNOEAOJDXEOAF-UHFFFAOYSA-N 0.000 description 1
- PJOOPVLLOKKKHQ-UHFFFAOYSA-N 3,5-dichloro-n-(5-oxo-7,8-dihydro-6h-naphthalen-2-yl)benzamide Chemical compound ClC1=CC(Cl)=CC(C(=O)NC=2C=C3CCCC(=O)C3=CC=2)=C1 PJOOPVLLOKKKHQ-UHFFFAOYSA-N 0.000 description 1
- WGILRKFDDKAMPP-UHFFFAOYSA-N 3,5-dichloro-n-(thiophen-2-ylmethyl)benzamide Chemical compound ClC1=CC(Cl)=CC(C(=O)NCC=2SC=CC=2)=C1 WGILRKFDDKAMPP-UHFFFAOYSA-N 0.000 description 1
- KKWWFYAKOFXBEY-UHFFFAOYSA-N 3-(chloromethyl)thiophene Chemical compound ClCC=1C=CSC=1 KKWWFYAKOFXBEY-UHFFFAOYSA-N 0.000 description 1
- 102000009878 3-Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- 108010020420 3-Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
- FBTVTBXDNLWGKZ-UHFFFAOYSA-N 3-chloro-2-methyl-n,n-bis(thiophen-3-ylmethyl)benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)N(CC1=CSC=C1)CC1=CSC=C1 FBTVTBXDNLWGKZ-UHFFFAOYSA-N 0.000 description 1
- DFFCEDOSRHUTEN-UHFFFAOYSA-N 3-chloro-2-methyl-n-(1-methylindazol-5-yl)benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=CC=C(N(C)N=C2)C2=C1 DFFCEDOSRHUTEN-UHFFFAOYSA-N 0.000 description 1
- FKYJLSGQYCWUJH-UHFFFAOYSA-N 3-chloro-2-methyl-n-(2-methyl-1,3-dioxoisoindol-5-yl)benzenesulfonamide Chemical compound C1=C2C(=O)N(C)C(=O)C2=CC=C1NS(=O)(=O)C1=CC=CC(Cl)=C1C FKYJLSGQYCWUJH-UHFFFAOYSA-N 0.000 description 1
- SNLNKERHPFIEEO-UHFFFAOYSA-N 3-chloro-2-methyl-n-(2-methyl-1-benzofuran-5-yl)benzenesulfonamide Chemical compound C=1C=C2OC(C)=CC2=CC=1NS(=O)(=O)C1=CC=CC(Cl)=C1C SNLNKERHPFIEEO-UHFFFAOYSA-N 0.000 description 1
- YCQCETMGKHNLMA-UHFFFAOYSA-N 3-chloro-2-methyl-n-(2-thiophen-2-ylethyl)benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NCCC1=CC=CS1 YCQCETMGKHNLMA-UHFFFAOYSA-N 0.000 description 1
- ACSIBZKOTUCLGE-UHFFFAOYSA-N 3-chloro-2-methyl-n-(3-oxo-1h-2-benzofuran-5-yl)benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=CC=C(COC2=O)C2=C1 ACSIBZKOTUCLGE-UHFFFAOYSA-N 0.000 description 1
- FUHPXTWXZVOKIR-UHFFFAOYSA-N 3-chloro-2-methyl-n-(4-morpholin-4-ylphenyl)benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=CC=C(N2CCOCC2)C=C1 FUHPXTWXZVOKIR-UHFFFAOYSA-N 0.000 description 1
- SGXMECMGJWSWFF-UHFFFAOYSA-N 3-chloro-2-methyl-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 SGXMECMGJWSWFF-UHFFFAOYSA-N 0.000 description 1
- OURKLECTYBWSCS-UHFFFAOYSA-N 3-chloro-2-methyl-n-(9-oxofluoren-3-yl)benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=CC=C(C(=O)C=2C3=CC=CC=2)C3=C1 OURKLECTYBWSCS-UHFFFAOYSA-N 0.000 description 1
- HCNJSNDACVCZLU-UHFFFAOYSA-N 3-chloro-2-methyl-n-(thiophen-2-ylmethyl)benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NCC1=CC=CS1 HCNJSNDACVCZLU-UHFFFAOYSA-N 0.000 description 1
- XHBBSJASNSNOOT-UHFFFAOYSA-N 3-chloro-2-methyl-n-(thiophen-3-ylmethyl)benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NCC1=CSC=C1 XHBBSJASNSNOOT-UHFFFAOYSA-N 0.000 description 1
- KQWNFBKORYLOPT-UHFFFAOYSA-N 3-chloro-4-[(3,4-dimethoxyphenyl)sulfonylamino]-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)NC1=CC=C(S(=O)(=O)NC2=NOC(C)=C2)C=C1Cl KQWNFBKORYLOPT-UHFFFAOYSA-N 0.000 description 1
- NZNIOICGWBSVOE-UHFFFAOYSA-N 3-chloro-4-[(4-methoxyphenyl)sulfonylamino]-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=C(S(=O)(=O)NC2=NOC(C)=C2)C=C1Cl NZNIOICGWBSVOE-UHFFFAOYSA-N 0.000 description 1
- JHMBQMVFOAGZKD-UHFFFAOYSA-N 3-chloro-n-(1h-indazol-5-yl)-2-methylbenzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=CC=C(NN=C2)C2=C1 JHMBQMVFOAGZKD-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- QUHMXFMRKACEMS-UHFFFAOYSA-N 3-methoxy-n-(1-oxo-2,3-dihydroinden-5-yl)benzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C3CCC(=O)C3=CC=2)=C1 QUHMXFMRKACEMS-UHFFFAOYSA-N 0.000 description 1
- JIVIUHVKBQSYKW-UHFFFAOYSA-N 3-methoxy-n-(2-thiophen-2-ylethyl)benzamide Chemical compound COC1=CC=CC(C(=O)NCCC=2SC=CC=2)=C1 JIVIUHVKBQSYKW-UHFFFAOYSA-N 0.000 description 1
- RCPZMRMSIOJNEK-UHFFFAOYSA-N 3-methoxy-n-(thiophen-2-ylmethyl)benzamide Chemical compound COC1=CC=CC(C(=O)NCC=2SC=CC=2)=C1 RCPZMRMSIOJNEK-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- JDWREWOCOCHHOO-UHFFFAOYSA-N 4-methoxy-2,3,6-trimethylbenzenesulfonic acid Chemical compound COC1=CC(C)=C(S(O)(=O)=O)C(C)=C1C JDWREWOCOCHHOO-UHFFFAOYSA-N 0.000 description 1
- BDTNSWXVHKMYTM-UHFFFAOYSA-N 4-methoxy-n-(1-oxo-2,3-dihydroinden-5-yl)benzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=C(C(=O)CC2)C2=C1 BDTNSWXVHKMYTM-UHFFFAOYSA-N 0.000 description 1
- VZECOARXTWABMF-UHFFFAOYSA-N 4-methoxy-n-(2-thiophen-2-ylethyl)benzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NCCC1=CC=CS1 VZECOARXTWABMF-UHFFFAOYSA-N 0.000 description 1
- HWVOHZJTRWCVSC-UHFFFAOYSA-N 4-methoxy-n-(thiophen-2-ylmethyl)benzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NCC1=CC=CS1 HWVOHZJTRWCVSC-UHFFFAOYSA-N 0.000 description 1
- IWYVYUZADLIDEY-UHFFFAOYSA-N 4-methoxybenzenesulfonic acid Chemical compound COC1=CC=C(S(O)(=O)=O)C=C1 IWYVYUZADLIDEY-UHFFFAOYSA-N 0.000 description 1
- XTXSECLMELRMHN-UHFFFAOYSA-N 4-phenoxy-n-(thiophen-2-ylmethyl)benzenesulfonamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1S(=O)(=O)NCC1=CC=CS1 XTXSECLMELRMHN-UHFFFAOYSA-N 0.000 description 1
- RHPCPGJYHDZYBJ-UHFFFAOYSA-N 4-phenyl-n,n-bis(thiophen-3-ylmethyl)benzenesulfonamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1S(=O)(=O)N(CC1=CSC=C1)CC=1C=CSC=1 RHPCPGJYHDZYBJ-UHFFFAOYSA-N 0.000 description 1
- JNLZGBFKPDGOKU-UHFFFAOYSA-N 4-phenyl-n-(2-thiophen-2-ylethyl)benzamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(=O)NCCC1=CC=CS1 JNLZGBFKPDGOKU-UHFFFAOYSA-N 0.000 description 1
- UUUFMXNQIIZZBM-UHFFFAOYSA-N 4-phenyl-n-(2-thiophen-2-ylethyl)benzenesulfonamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1S(=O)(=O)NCCC1=CC=CS1 UUUFMXNQIIZZBM-UHFFFAOYSA-N 0.000 description 1
- ZQOKKHISKXANAP-UHFFFAOYSA-N 4-phenyl-n-(thiophen-2-ylmethyl)benzamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(=O)NCC1=CC=CS1 ZQOKKHISKXANAP-UHFFFAOYSA-N 0.000 description 1
- OGTBJPAAKWJSSZ-UHFFFAOYSA-N 4-phenyl-n-(thiophen-2-ylmethyl)benzenesulfonamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1S(=O)(=O)NCC1=CC=CS1 OGTBJPAAKWJSSZ-UHFFFAOYSA-N 0.000 description 1
- AMPYJEMMBLPXLT-UHFFFAOYSA-N 4-phenyl-n-(thiophen-3-ylmethyl)benzenesulfonamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1S(=O)(=O)NCC=1C=CSC=1 AMPYJEMMBLPXLT-UHFFFAOYSA-N 0.000 description 1
- XDTYUYVIGLIFCW-UHFFFAOYSA-N 4-phenylbenzenesulfonic acid Chemical compound C1=CC(S(=O)(=O)O)=CC=C1C1=CC=CC=C1 XDTYUYVIGLIFCW-UHFFFAOYSA-N 0.000 description 1
- PFWJNYSDQHSUFB-UHFFFAOYSA-N 4-propyl-n,n-bis(thiophen-3-ylmethyl)benzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N(CC1=CSC=C1)CC1=CSC=C1 PFWJNYSDQHSUFB-UHFFFAOYSA-N 0.000 description 1
- YGFBAMMIXFPGKW-UHFFFAOYSA-N 4-propyl-n-(2-thiophen-2-ylethyl)benzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)NCCC1=CC=CS1 YGFBAMMIXFPGKW-UHFFFAOYSA-N 0.000 description 1
- MBIVYAKDWKVBTI-UHFFFAOYSA-N 4-propyl-n-(2-thiophen-2-ylethyl)benzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NCCC1=CC=CS1 MBIVYAKDWKVBTI-UHFFFAOYSA-N 0.000 description 1
- MLBCBKSTBATBLZ-UHFFFAOYSA-N 4-propyl-n-(thiophen-2-ylmethyl)benzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)NCC1=CC=CS1 MLBCBKSTBATBLZ-UHFFFAOYSA-N 0.000 description 1
- ISHOUKQKQSZMNW-UHFFFAOYSA-N 4-propyl-n-(thiophen-2-ylmethyl)benzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NCC1=CC=CS1 ISHOUKQKQSZMNW-UHFFFAOYSA-N 0.000 description 1
- JRIFYXDWWDZEGY-UHFFFAOYSA-N 4-propyl-n-(thiophen-3-ylmethyl)benzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NCC1=CSC=C1 JRIFYXDWWDZEGY-UHFFFAOYSA-N 0.000 description 1
- KRFQAVUFGKIXSK-UHFFFAOYSA-N 5-(bromomethyl)-2-methyl-1,3-benzothiazole Chemical compound BrCC1=CC=C2SC(C)=NC2=C1 KRFQAVUFGKIXSK-UHFFFAOYSA-N 0.000 description 1
- BKAAOVUHPSMVMB-UHFFFAOYSA-N 5-[(2,5-dichlorophenyl)sulfonylmethyl]-2-methyl-1,3-benzothiazole Chemical compound C=1C=C2SC(C)=NC2=CC=1CS(=O)(=O)C1=CC(Cl)=CC=C1Cl BKAAOVUHPSMVMB-UHFFFAOYSA-N 0.000 description 1
- LDTCWISGJYTXDC-UHFFFAOYSA-N 5-nitro-1,2-benzothiazol-3-amine Chemical compound C1=C([N+]([O-])=O)C=C2C(N)=NSC2=C1 LDTCWISGJYTXDC-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- KNHXROGQGUBRAU-UHFFFAOYSA-N C=1C=C2N(C)C(C)NC2=CC=1N(C)C(=O)C(C=C1)=CC=C1C1=CC=CC=C1 Chemical compound C=1C=C2N(C)C(C)NC2=CC=1N(C)C(=O)C(C=C1)=CC=C1C1=CC=CC=C1 KNHXROGQGUBRAU-UHFFFAOYSA-N 0.000 description 1
- FXYZAFDQVJHSCQ-UHFFFAOYSA-N C=1C=C2N(C)C(C)NC2=CC=1NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 Chemical compound C=1C=C2N(C)C(C)NC2=CC=1NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 FXYZAFDQVJHSCQ-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108700011498 Glucocorticoid Receptor Deficiency Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- 108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108050009288 Interleukin-19 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000234269 Liliales Species 0.000 description 1
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010035138 Placental insufficiency Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 102000034755 Sex Hormone-Binding Globulin Human genes 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000009134 Steryl-Sulfatase Human genes 0.000 description 1
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 208000011622 Testicular disease Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- RVKFQAJIXCZXQY-CBZIJGRNSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] sulfamate Chemical compound NS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 RVKFQAJIXCZXQY-CBZIJGRNSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000006193 alkinyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000009262 apparent mineralocorticoid excess Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 150000001500 aryl chlorides Chemical class 0.000 description 1
- 125000005362 aryl sulfone group Chemical group 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 239000013584 assay control Substances 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 150000008316 benzisoxazoles Chemical class 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 150000004802 benzothiophens Chemical class 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001659 chemokinetic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 125000003306 cortisone group Chemical group 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000001236 detergent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- ZZDJNZGVEYDPIW-UHFFFAOYSA-N ethyl 3-amino-1-(3-chloro-2-methylphenyl)sulfonylpyrazole-4-carboxylate Chemical compound N1=C(N)C(C(=O)OCC)=CN1S(=O)(=O)C1=CC=CC(Cl)=C1C ZZDJNZGVEYDPIW-UHFFFAOYSA-N 0.000 description 1
- ZBXYQJSNSPLQRE-UHFFFAOYSA-N ethyl 5-[(3-chloro-2-methylphenyl)sulfonylamino]-1-methylpyrazole-4-carboxylate Chemical compound C1=NN(C)C(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=C1C(=O)OCC ZBXYQJSNSPLQRE-UHFFFAOYSA-N 0.000 description 1
- BQJNUIVHQHGJDV-UHFFFAOYSA-N ethyl 5-amino-1-(3-chloro-2-methylphenyl)sulfonylpyrazole-4-carboxylate Chemical compound NC1=C(C(=O)OCC)C=NN1S(=O)(=O)C1=CC=CC(Cl)=C1C BQJNUIVHQHGJDV-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000026352 glucocorticoid resistance Diseases 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000000396 hypokalemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 231100000253 induce tumour Toxicity 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000002415 kinetochore Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- JUEBDNBXRJTAHN-UHFFFAOYSA-N methyl 5-[(3-chloro-2-methylphenyl)sulfonylamino]-1-benzofuran-2-carboxylate Chemical compound C=1C=C2OC(C(=O)OC)=CC2=CC=1NS(=O)(=O)C1=CC=CC(Cl)=C1C JUEBDNBXRJTAHN-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- VSPPONOIKZXUBJ-UHFFFAOYSA-N n,n-diethylethanamine;oxolane Chemical compound C1CCOC1.CCN(CC)CC VSPPONOIKZXUBJ-UHFFFAOYSA-N 0.000 description 1
- LIGRCHUSTVISGN-UHFFFAOYSA-N n-(1,2-dimethylbenzimidazol-5-yl)-4-propylbenzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)NC1=CC=C(N(C)C(C)=N2)C2=C1 LIGRCHUSTVISGN-UHFFFAOYSA-N 0.000 description 1
- MKXFXJAQICZWTE-UHFFFAOYSA-N n-(1-benzothiophen-2-ylmethyl)-2,5-dichlorobenzenesulfonamide Chemical compound ClC1=CC=C(Cl)C(S(=O)(=O)NCC=2SC3=CC=CC=C3C=2)=C1 MKXFXJAQICZWTE-UHFFFAOYSA-N 0.000 description 1
- JTVUSJXOAZPYAX-UHFFFAOYSA-N n-(1-benzothiophen-2-ylmethyl)-3,5-dichlorobenzamide Chemical compound ClC1=CC(Cl)=CC(C(=O)NCC=2SC3=CC=CC=C3C=2)=C1 JTVUSJXOAZPYAX-UHFFFAOYSA-N 0.000 description 1
- SGXJWVALEOVWSK-UHFFFAOYSA-N n-(1-benzothiophen-2-ylmethyl)-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NCC1=CC2=CC=CC=C2S1 SGXJWVALEOVWSK-UHFFFAOYSA-N 0.000 description 1
- REMMURDMZNIVJD-UHFFFAOYSA-N n-(1-benzothiophen-2-ylmethyl)-4-propylbenzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)NCC1=CC2=CC=CC=C2S1 REMMURDMZNIVJD-UHFFFAOYSA-N 0.000 description 1
- OWRZFSHCZVTHBD-UHFFFAOYSA-N n-(1-benzothiophen-2-ylmethyl)-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NCC1=CC2=CC=CC=C2S1 OWRZFSHCZVTHBD-UHFFFAOYSA-N 0.000 description 1
- RFOSSSCMEMCALF-UHFFFAOYSA-N n-(1-oxo-2,3-dihydroinden-5-yl)-4-propylbenzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)NC1=CC=C(C(=O)CC2)C2=C1 RFOSSSCMEMCALF-UHFFFAOYSA-N 0.000 description 1
- LFTQOXCPEQKDRO-UHFFFAOYSA-N n-(2,3-dimethyl-1,2-dihydrobenzimidazol-5-yl)-4-phenylbenzamide Chemical compound C1=C2N(C)C(C)NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 LFTQOXCPEQKDRO-UHFFFAOYSA-N 0.000 description 1
- TVMWODDXCKOUGQ-UHFFFAOYSA-N n-(2,6-dimethoxypyridin-3-yl)-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=CC=C(OC)N=C1OC TVMWODDXCKOUGQ-UHFFFAOYSA-N 0.000 description 1
- NDZQAMINFQTAOP-UHFFFAOYSA-N n-(2-ethylpyrazol-3-yl)-4-propyl-n-(4-propylphenyl)sulfonylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N(S(=O)(=O)C=1C=CC(CCC)=CC=1)C1=CC=NN1CC NDZQAMINFQTAOP-UHFFFAOYSA-N 0.000 description 1
- DBHHUPHXIPVIOG-UHFFFAOYSA-N n-(4-benzoylphenyl)-3,5-dichlorobenzamide Chemical compound ClC1=CC(Cl)=CC(C(=O)NC=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)=C1 DBHHUPHXIPVIOG-UHFFFAOYSA-N 0.000 description 1
- IVCGOEBBXRGNLH-UHFFFAOYSA-N n-(4-benzoylphenyl)-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)=C1 IVCGOEBBXRGNLH-UHFFFAOYSA-N 0.000 description 1
- NXWXNRBMJSRGGR-UHFFFAOYSA-N n-(4-benzoylphenyl)-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=C(C(=O)C=2C=CC=CC=2)C=C1 NXWXNRBMJSRGGR-UHFFFAOYSA-N 0.000 description 1
- GGIKJLZDFDWKGJ-UHFFFAOYSA-N n-(4-benzoylphenyl)-4-phenylbenzamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(=O)NC(C=C1)=CC=C1C(=O)C1=CC=CC=C1 GGIKJLZDFDWKGJ-UHFFFAOYSA-N 0.000 description 1
- TUAKDAQCCZCYBI-UHFFFAOYSA-N n-(4-benzoylphenyl)-4-propylbenzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)NC1=CC=C(C(=O)C=2C=CC=CC=2)C=C1 TUAKDAQCCZCYBI-UHFFFAOYSA-N 0.000 description 1
- WJTNTFJLOORBJT-UHFFFAOYSA-N n-(4-chloro-2-methyl-1,3-benzothiazol-5-yl)-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=C3N=C(C)SC3=CC=2)Cl)=C1 WJTNTFJLOORBJT-UHFFFAOYSA-N 0.000 description 1
- FYYGPDXTQDCGJE-UHFFFAOYSA-N n-(4-chloro-2-methyl-1,3-benzothiazol-5-yl)-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=C(SC(C)=N2)C2=C1Cl FYYGPDXTQDCGJE-UHFFFAOYSA-N 0.000 description 1
- YXHCGKBDQMEHAZ-UHFFFAOYSA-N n-(5-methyl-1,2-oxazol-3-yl)-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=NOC(C)=C1 YXHCGKBDQMEHAZ-UHFFFAOYSA-N 0.000 description 1
- BGCGPCCNXOODGR-UHFFFAOYSA-N n-(6-methoxypyridin-3-yl)-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=CC=C(OC)N=C1 BGCGPCCNXOODGR-UHFFFAOYSA-N 0.000 description 1
- YEOPDUXJGNFZEH-UHFFFAOYSA-N n-[2-chloro-4-[(5-methyl-1,2-oxazol-3-yl)sulfamoyl]phenyl]acetamide Chemical compound C1=C(Cl)C(NC(=O)C)=CC=C1S(=O)(=O)NC1=NOC(C)=C1 YEOPDUXJGNFZEH-UHFFFAOYSA-N 0.000 description 1
- WBVCAIHXLOUOEE-UHFFFAOYSA-N n-acetyl-n-(5-nitro-1,2-benzothiazol-3-yl)acetamide Chemical compound C1=C([N+]([O-])=O)C=C2C(N(C(C)=O)C(=O)C)=NSC2=C1 WBVCAIHXLOUOEE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- UGIYNQVYDMGKHT-UHFFFAOYSA-N n-methyl-n-(2-methyl-1,3-benzothiazol-5-yl)-4-propylbenzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)N(C)C1=CC=C(SC(C)=N2)C2=C1 UGIYNQVYDMGKHT-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003252 quinoxalines Chemical class 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 230000017162 regulation of protein metabolic process Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003198 secondary alcohol group Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000037359 steroid metabolism Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000002948 striated muscle cell Anatomy 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- GLQWRXYOTXRDNH-UHFFFAOYSA-N thiophen-2-amine Chemical compound NC1=CC=CS1 GLQWRXYOTXRDNH-UHFFFAOYSA-N 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/40—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51321703P | 2003-10-23 | 2003-10-23 | |
| US60/513,217 | 2003-10-23 | ||
| GB0324792.1 | 2003-10-23 | ||
| GBGB0324792.1A GB0324792D0 (en) | 2003-10-23 | 2003-10-23 | Compound |
| PCT/GB2004/004498 WO2005042513A1 (fr) | 2003-10-23 | 2004-10-22 | Derives de carboxamide de phenyle et de sulfonamide utilisables comme 11-beta-hydroxysteroide deshydrogenase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2540843A1 true CA2540843A1 (fr) | 2005-05-12 |
Family
ID=34553793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002540843A Abandoned CA2540843A1 (fr) | 2003-10-23 | 2004-10-22 | Derives de carboxamide de phenyle et de sulfonamide utilisables comme 11-beta-hydroxysteroide deshydrogenase |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1675844A1 (fr) |
| CA (1) | CA2540843A1 (fr) |
| WO (1) | WO2005042513A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2005108370A1 (ja) * | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| GB0408771D0 (en) * | 2004-04-20 | 2004-05-26 | Sterix Ltd | Compound |
| US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| WO2006074244A2 (fr) | 2005-01-05 | 2006-07-13 | Abbott Laboratories | Inhibiteurs de l'enzyme 11-beta-hydroxysteroide deshydrogenase de type 1 |
| JP5133702B2 (ja) | 2005-01-05 | 2013-01-30 | アボット・ラボラトリーズ | 11−β−ヒドロキシステロイドデヒドロゲナーゼ1型酵素の阻害薬 |
| US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| EP1866298A2 (fr) | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Inhibiteurs de l'hydroxysteroide deshydrogenase |
| CA2614746C (fr) | 2005-07-09 | 2011-05-10 | Astrazeneca Ab | Derives d'heteroaryl benzamide utilises en tant qu'activateurs de la glk dans le traitement du diabete |
| US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
| BRPI0710479A2 (pt) | 2006-01-18 | 2012-08-14 | Hoffmann La Roche | composto, processo para sua preparaÇço, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento de doenÇa ou desosrdem metabàlica. |
| JP2009534365A (ja) * | 2006-04-21 | 2009-09-24 | アストラゼネカ アクチボラグ | Adg受容体修飾物質として有用なスルホンアミド化合物 |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
| ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
| TW201210597A (en) * | 2010-06-09 | 2012-03-16 | Gilead Sciences Inc | Inhibitors of hepatitis C virus |
| WO2012071414A2 (fr) * | 2010-11-22 | 2012-05-31 | Board Of Regents Of The University Of Nebraska | Composés de quinoxaline et leurs utilisations |
| ME02733B (fr) * | 2011-10-18 | 2017-10-20 | Astellas Pharma Inc | Composé hétérocyclique bicyclique |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| CN105085427B (zh) * | 2015-08-21 | 2018-06-05 | 中国科学院广州生物医药与健康研究院 | 一类苯并[d]异恶唑类化合物及其应用 |
| CN118103038A (zh) * | 2021-08-20 | 2024-05-28 | 英安塔制药有限公司 | 17β-羟基类固醇脱氢酶13型抑制剂及其使用方法 |
| IL316789A (en) * | 2022-06-07 | 2025-01-01 | Sironax Ltd | SARM1 modulators, their preparation and use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB828963A (en) * | 1956-08-03 | 1960-02-24 | Rhone Poulenc Sa | Pharmaceutical compositions containing 2-p-aminobenzenesulphonamido-5-t-butyl-1, 3, 4-thiadiazole |
| GB822947A (en) * | 1957-01-25 | 1959-11-04 | Smith & Nephew | Improvements in and relating to sulphonamides |
| IE31812B1 (en) * | 1967-02-03 | 1973-01-10 | Merck & Co Inc | Benzimidazole derivatives |
| AU2002353716A1 (en) * | 2001-11-22 | 2003-06-10 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| WO2003044000A1 (fr) * | 2001-11-22 | 2003-05-30 | Biovitrum Ab | Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1 |
-
2004
- 2004-10-22 CA CA002540843A patent/CA2540843A1/fr not_active Abandoned
- 2004-10-22 EP EP04791576A patent/EP1675844A1/fr not_active Withdrawn
- 2004-10-22 WO PCT/GB2004/004498 patent/WO2005042513A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1675844A1 (fr) | 2006-07-05 |
| WO2005042513A1 (fr) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2540843A1 (fr) | Derives de carboxamide de phenyle et de sulfonamide utilisables comme 11-beta-hydroxysteroide deshydrogenase | |
| US20090042929A1 (en) | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | |
| KR101715190B1 (ko) | 제약 화합물 | |
| EP2599771B1 (fr) | Dérivé de naphtalène | |
| US7230020B2 (en) | 11β-hydroxysteroid dehydrogenase inhibitors | |
| WO2004037251A1 (fr) | Inhibiteurs de 11-beta-hydroxy steroide dehydrogenase de type 1 et de type 2 | |
| US20040002524A1 (en) | Benzimidazole compounds and their use as estrogen agonists/antagonists | |
| EP2460787A1 (fr) | Composés d'amide et leur utilidsation comme anagonistes de la PGE2. | |
| EP0979228A1 (fr) | Nouveaux agonistes de recepteurs de cannabinoides | |
| CN107098846B (zh) | N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途 | |
| JP2002293768A (ja) | フェニルスルファメート誘導体 | |
| AU2009211215A1 (en) | Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid | |
| JP2003523961A (ja) | 小グリア細胞活性化に関連する疾病の処理のための1,2−ジアリールベンズイミダゾール | |
| EP0526001A1 (fr) | Triazolinones substitués | |
| US20070244108A1 (en) | Phenylsulfonamide Derivatives for Use as 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | |
| CA2464770C (fr) | Compose | |
| US7786152B2 (en) | Compound | |
| US20100120789A1 (en) | Compound | |
| CA2632437C (fr) | Derives de 1,2,4-triazol-l-yl bisphenyle utilises pour le traitement de tumeurs a dependance endocrinienne | |
| US7345075B2 (en) | 1,2 diarylbenzimidazoles and their pharmaceutical use | |
| Wright et al. | 2, 5-Diarylisothiazolone: novel inhibitors of cytokine-induced cartilage destruction | |
| US5789419A (en) | 4-quinolinone derivative or salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20130916 |